You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
|
|---|---|
| Published in |
BMC Cancer, August 2013
|
| DOI | 10.1186/1471-2407-13-386 |
| Pubmed ID | |
| Authors |
Igor Bondarenko, Oleg A Gladkov, Reiner Elsaesser, Anton Buchner, Peter Bias |
| Abstract |
Lipegfilgrastim is a novel glyco-pegylated granulocyte-colony stimulating factor in development for neutropenia prophylaxis in cancer patients receiving chemotherapy. This phase III, double-blind, randomized, active-controlled, noninferiority trial compared the efficacy and safety of lipegfilgrastim versus pegfilgrastim in chemotherapy-naive breast cancer patients receiving doxorubicin/docetaxel chemotherapy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 65 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 18% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Master | 7 | 11% |
| Other | 6 | 9% |
| Lecturer | 5 | 8% |
| Other | 13 | 20% |
| Unknown | 15 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 31% |
| Nursing and Health Professions | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Agricultural and Biological Sciences | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Other | 9 | 14% |
| Unknown | 20 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2013.
All research outputs
#20,198,525
of 22,716,996 outputs
Outputs from BMC Cancer
#6,487
of 8,266 outputs
Outputs of similar age
#172,190
of 196,389 outputs
Outputs of similar age from BMC Cancer
#62
of 68 outputs
Altmetric has tracked 22,716,996 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,266 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 196,389 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.